Lurasidone Impurity 51 - Request Quote
Lurasidone Impurity 51
| SZ CAT No: | SZ-L035077 |
| CAS No | NA |
| Mol.F. | C28H36N4O2S : HCl |
| Mol.Wt. | 492.7 : 36.5 |
| Inv. Status | Synthesis on demand |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Lurasidone Impurity 51 is chemically (3aR,4S,7R,7aS)-2-(((1S,2R)-2-((4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)cyclohexyl)methyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione hydrochloride. Lurasidone Impurity 51 is supplied with detailed characterization data compliant with regulatory guideline. Lurasidone Impurity 51 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Lurasidone.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
buy high quality Lurasidone Impurity 51
Purchase Lurasidone Impurity 51
Lurasidone Impurity 51 suppliers
Lurasidone Impurity 51 manufacturers
Lurasidone Impurity 51 price
Order Lurasidone Impurity 51
Enquire Lurasidone Impurity 51
Lurasidone Impurity 51 cost
Lurasidone Impurity 51 Supplier
Lurasidone Impurity 51 Distributor
Lurasidone Impurity 51 for Method Validation
Lurasidone Reference Standard
Lurasidone Impurity 51 for ANDA Filing
Lurasidone Impurity 51 for Forced Degradation Studies
Lurasidone Impurity 51 Identification Standards
Lurasidone Impurity 51 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


